US Stock MarketDetailed Quotes

MRK Merck & Co

Watchlist
  • 99.750
  • -1.250-1.24%
Close Dec 11 16:00 ET
  • 100.860
  • +1.110+1.11%
Pre 06:31 ET
252.33BMarket Cap20.87P/E (TTM)

Merck & Co Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
20.40%9.29B
52.19%5.64B
130.77%3.09B
-31.89%13.01B
-94.45%246M
37.75%7.72B
-13.90%3.7B
-71.88%1.34B
45.52%19.1B
-13.05%4.43B
Net income from continuing operations
-33.45%3.16B
191.44%5.46B
68.74%4.77B
-97.40%377M
-140.62%-1.23B
46.06%4.75B
-251.23%-5.97B
-34.41%2.83B
17.54%14.53B
-21.08%3.02B
Operating gains losses
-8.82%31M
-132.39%-57M
68.22%-143M
-123.96%-340M
-272.41%-100M
-90.81%34M
-37.81%176M
-163.56%-450M
173.14%1.42B
114.32%58M
Depreciation and amortization
16.96%1.19B
25.36%1.13B
-0.71%984M
-0.95%3.87B
8.07%964M
5.74%1.01B
-3.73%903M
-11.52%991M
21.62%3.91B
6.83%892M
Deferred tax
-19.35%-401M
49.01%-181M
81.59%-51M
-21.11%-1.9B
-203.26%-931M
49.17%-336M
-35.50%-355M
18.05%-277M
-938.50%-1.57B
-293.08%-307M
Other non cash items
3,050.00%2.54B
-99.13%91M
-25.73%739M
804.23%11.76B
230.30%436M
-123.24%-86M
1,488.26%10.42B
595.80%995M
-44.90%1.3B
-56.86%132M
Change In working capital
18.60%2.58B
38.14%-1.01B
-17.02%-3.38B
20.74%-2.21B
141.50%144M
727.76%2.18B
-16.94%-1.64B
-122.48%-2.89B
27.53%-2.78B
-671.11%-347M
-Change in receivables
----
----
----
-78.26%-1.15B
----
----
----
----
68.32%-644M
----
-Change in inventory
----
----
----
-406.83%-816M
----
----
----
----
76.11%-161M
----
-Change in payables and accrued expense
----
----
----
3,843.90%1.62B
----
----
----
----
-71.13%41M
----
-Change in other current liabilities
----
----
----
183.67%456M
----
----
----
----
-212.60%-545M
----
-Change in other working capital
----
----
----
-57.09%-2.31B
----
----
----
----
16.21%-1.47B
----
Cash from discontinued investing activities
0
0
Operating cash flow
20.40%9.29B
52.19%5.64B
130.77%3.09B
-31.89%13.01B
-94.45%246M
37.75%7.72B
-13.90%3.7B
-71.88%1.34B
35.34%19.1B
-11.95%4.43B
Investing cash flow
Cash flow from continuing investing activities
-1,051.20%-3.85B
90.66%-1.07B
41.67%-1.38B
-183.93%-14.08B
103.03%53M
65.28%-334M
-962.49%-11.44B
-101.11%-2.36B
69.79%-4.96B
85.49%-1.75B
Capital expenditure reported
13.19%-783M
18.03%-791M
14.50%-861M
11.96%-3.86B
13.93%-989M
19.89%-902M
14.53%-965M
-2.34%-1.01B
1.35%-4.39B
4.88%-1.15B
Net business purchase and sale
---3.35B
--0
43.78%-746M
-9,843.80%-12.03B
--0
--0
---10.71B
---1.33B
99.06%-121M
--0
Net investment purchase and sale
-91.48%50M
-95.77%11M
495.16%245M
482.61%1.85B
320.54%1.06B
77.88%587M
550.00%260M
83.29%-62M
-147.12%-483M
-191.12%-482M
Net other investing changes
1,326.32%233M
-775.76%-289M
-137.84%-14M
-212.50%-36M
82.05%-21M
57.78%-19M
-375.00%-33M
-79.67%37M
135.16%32M
-10.38%-117M
Cash from discontinued investing activities
Investing cash flow
-1,051.20%-3.85B
90.66%-1.07B
41.67%-1.38B
-183.93%-14.08B
103.03%53M
65.28%-334M
-962.49%-11.44B
-101.11%-2.36B
70.04%-4.96B
85.49%-1.75B
Financing cash flow
Cash flow from continuing financing activities
43.20%-2.43B
-67.64%1.22B
-37.00%-2.81B
47.25%-4.81B
-44.47%-2.25B
-57.99%-4.27B
311.48%3.76B
33.44%-2.05B
-394.45%-9.12B
-129.84%-1.55B
Net issuance payments of debt
99.95%-1M
-41.30%3.6B
-75,000.00%-751M
285.87%4.18B
-200.00%-3M
-94.50%-1.95B
--6.13B
99.92%-1M
-238.01%-2.25B
-100.01%-1M
Net common stock issuance
4.72%-444M
25.74%-251M
18.12%-122M
---1.35B
---393M
---466M
---338M
---149M
--0
--0
Cash dividends paid
-5.28%-1.95B
-5.36%-1.99B
-5.23%-1.95B
-6.18%-7.45B
-5.83%-1.85B
-6.18%-1.86B
-6.50%-1.89B
-6.19%-1.85B
-6.08%-7.01B
-6.51%-1.75B
Proceeds from stock option exercised by employees
-28.57%5M
-10.98%73M
190.00%87M
-67.45%125M
-97.74%6M
-30.00%7M
-15.46%82M
150.00%30M
90.10%384M
97.76%265M
Net other financing activities
-220.00%-32M
5.98%-220M
3.70%-78M
-36.67%-328M
95.59%-3M
-128.57%-10M
-125.00%-234M
21.36%-81M
-102.75%-240M
-106.06%-68M
Cash from discontinued financing activities
0
0
Financing cash flow
43.20%-2.43B
-67.64%1.22B
-37.00%-2.81B
47.25%-4.81B
-44.47%-2.25B
-57.99%-4.27B
311.48%3.76B
33.44%-2.05B
-451.68%-9.12B
-129.84%-1.55B
Net cash flow
Beginning cash position
99.11%11.37B
-42.05%5.67B
-45.91%6.91B
56.40%12.77B
-23.14%8.67B
-41.43%5.71B
13.61%9.79B
56.40%12.77B
0.17%8.17B
12.27%11.28B
Current changes in cash
-2.99%3.02B
245.29%5.78B
64.22%-1.1B
-217.36%-5.89B
-272.52%-1.95B
60.68%3.11B
-374.93%-3.98B
-712.35%-3.07B
3,312.24%5.02B
162.29%1.13B
Effect of exchange rate changes
287.26%294M
11.83%-82M
-258.62%-138M
105.61%23M
-49.18%186M
61.89%-157M
69.90%-93M
258.18%87M
-208.27%-410M
638.24%366M
End cash Position
69.43%14.69B
99.11%11.37B
-42.05%5.67B
-45.91%6.91B
-45.91%6.91B
-23.14%8.67B
-41.43%5.71B
13.61%9.79B
56.40%12.77B
56.40%12.77B
Free cash flow
24.84%8.51B
76.93%4.85B
571.39%2.23B
-37.83%9.14B
-122.65%-743M
52.26%6.82B
-13.68%2.74B
-91.21%332M
52.23%14.71B
-14.18%3.28B
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
--
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 20.40%9.29B52.19%5.64B130.77%3.09B-31.89%13.01B-94.45%246M37.75%7.72B-13.90%3.7B-71.88%1.34B45.52%19.1B-13.05%4.43B
Net income from continuing operations -33.45%3.16B191.44%5.46B68.74%4.77B-97.40%377M-140.62%-1.23B46.06%4.75B-251.23%-5.97B-34.41%2.83B17.54%14.53B-21.08%3.02B
Operating gains losses -8.82%31M-132.39%-57M68.22%-143M-123.96%-340M-272.41%-100M-90.81%34M-37.81%176M-163.56%-450M173.14%1.42B114.32%58M
Depreciation and amortization 16.96%1.19B25.36%1.13B-0.71%984M-0.95%3.87B8.07%964M5.74%1.01B-3.73%903M-11.52%991M21.62%3.91B6.83%892M
Deferred tax -19.35%-401M49.01%-181M81.59%-51M-21.11%-1.9B-203.26%-931M49.17%-336M-35.50%-355M18.05%-277M-938.50%-1.57B-293.08%-307M
Other non cash items 3,050.00%2.54B-99.13%91M-25.73%739M804.23%11.76B230.30%436M-123.24%-86M1,488.26%10.42B595.80%995M-44.90%1.3B-56.86%132M
Change In working capital 18.60%2.58B38.14%-1.01B-17.02%-3.38B20.74%-2.21B141.50%144M727.76%2.18B-16.94%-1.64B-122.48%-2.89B27.53%-2.78B-671.11%-347M
-Change in receivables -------------78.26%-1.15B----------------68.32%-644M----
-Change in inventory -------------406.83%-816M----------------76.11%-161M----
-Change in payables and accrued expense ------------3,843.90%1.62B-----------------71.13%41M----
-Change in other current liabilities ------------183.67%456M-----------------212.60%-545M----
-Change in other working capital -------------57.09%-2.31B----------------16.21%-1.47B----
Cash from discontinued investing activities 00
Operating cash flow 20.40%9.29B52.19%5.64B130.77%3.09B-31.89%13.01B-94.45%246M37.75%7.72B-13.90%3.7B-71.88%1.34B35.34%19.1B-11.95%4.43B
Investing cash flow
Cash flow from continuing investing activities -1,051.20%-3.85B90.66%-1.07B41.67%-1.38B-183.93%-14.08B103.03%53M65.28%-334M-962.49%-11.44B-101.11%-2.36B69.79%-4.96B85.49%-1.75B
Capital expenditure reported 13.19%-783M18.03%-791M14.50%-861M11.96%-3.86B13.93%-989M19.89%-902M14.53%-965M-2.34%-1.01B1.35%-4.39B4.88%-1.15B
Net business purchase and sale ---3.35B--043.78%-746M-9,843.80%-12.03B--0--0---10.71B---1.33B99.06%-121M--0
Net investment purchase and sale -91.48%50M-95.77%11M495.16%245M482.61%1.85B320.54%1.06B77.88%587M550.00%260M83.29%-62M-147.12%-483M-191.12%-482M
Net other investing changes 1,326.32%233M-775.76%-289M-137.84%-14M-212.50%-36M82.05%-21M57.78%-19M-375.00%-33M-79.67%37M135.16%32M-10.38%-117M
Cash from discontinued investing activities
Investing cash flow -1,051.20%-3.85B90.66%-1.07B41.67%-1.38B-183.93%-14.08B103.03%53M65.28%-334M-962.49%-11.44B-101.11%-2.36B70.04%-4.96B85.49%-1.75B
Financing cash flow
Cash flow from continuing financing activities 43.20%-2.43B-67.64%1.22B-37.00%-2.81B47.25%-4.81B-44.47%-2.25B-57.99%-4.27B311.48%3.76B33.44%-2.05B-394.45%-9.12B-129.84%-1.55B
Net issuance payments of debt 99.95%-1M-41.30%3.6B-75,000.00%-751M285.87%4.18B-200.00%-3M-94.50%-1.95B--6.13B99.92%-1M-238.01%-2.25B-100.01%-1M
Net common stock issuance 4.72%-444M25.74%-251M18.12%-122M---1.35B---393M---466M---338M---149M--0--0
Cash dividends paid -5.28%-1.95B-5.36%-1.99B-5.23%-1.95B-6.18%-7.45B-5.83%-1.85B-6.18%-1.86B-6.50%-1.89B-6.19%-1.85B-6.08%-7.01B-6.51%-1.75B
Proceeds from stock option exercised by employees -28.57%5M-10.98%73M190.00%87M-67.45%125M-97.74%6M-30.00%7M-15.46%82M150.00%30M90.10%384M97.76%265M
Net other financing activities -220.00%-32M5.98%-220M3.70%-78M-36.67%-328M95.59%-3M-128.57%-10M-125.00%-234M21.36%-81M-102.75%-240M-106.06%-68M
Cash from discontinued financing activities 00
Financing cash flow 43.20%-2.43B-67.64%1.22B-37.00%-2.81B47.25%-4.81B-44.47%-2.25B-57.99%-4.27B311.48%3.76B33.44%-2.05B-451.68%-9.12B-129.84%-1.55B
Net cash flow
Beginning cash position 99.11%11.37B-42.05%5.67B-45.91%6.91B56.40%12.77B-23.14%8.67B-41.43%5.71B13.61%9.79B56.40%12.77B0.17%8.17B12.27%11.28B
Current changes in cash -2.99%3.02B245.29%5.78B64.22%-1.1B-217.36%-5.89B-272.52%-1.95B60.68%3.11B-374.93%-3.98B-712.35%-3.07B3,312.24%5.02B162.29%1.13B
Effect of exchange rate changes 287.26%294M11.83%-82M-258.62%-138M105.61%23M-49.18%186M61.89%-157M69.90%-93M258.18%87M-208.27%-410M638.24%366M
End cash Position 69.43%14.69B99.11%11.37B-42.05%5.67B-45.91%6.91B-45.91%6.91B-23.14%8.67B-41.43%5.71B13.61%9.79B56.40%12.77B56.40%12.77B
Free cash flow 24.84%8.51B76.93%4.85B571.39%2.23B-37.83%9.14B-122.65%-743M52.26%6.82B-13.68%2.74B-91.21%332M52.23%14.71B-14.18%3.28B
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----------------Unqualified Opinion--
Heat List
US
Overall
Symbol
Price
% Chg

No Data

Investment Theme ESG Investing
ESG Investing
Intraday-0.34%
Infectious Disease
Infectious Disease
Intraday-0.59%
Cancer Research
Cancer Research
Intraday-1.09%